Neos Therapeutics, Inc. 4
4 · Neos Therapeutics, Inc. · Filed Jul 28, 2015
Insider Transaction Report
Form 4
HELLER ALAN L
Director
Transactions
- Conversion
Common Stock
2015-07-28+100,000→ 277,932 total - Exercise/Conversion
Stock Option (Right to Buy)
2015-07-27−28,897→ 0 totalExercise: $2.31Exp: 2022-11-14→ Common Stock (28,897 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2015-07-27−1,643→ 0 totalExercise: $0.32Exp: 2021-08-30→ Common Stock (1,643 underlying) - Conversion
Series B-1 Preferred Stock
2015-07-28−240,000→ 0 total→ Common Stock (100,000 underlying) - Exercise of In-Money
Common Stock
2015-07-27$0.02/sh+16,408$394→ 126,559 total - Exercise/Conversion
Common Stock
2015-07-27$0.32/sh+1,643$526→ 157,099 total - Conversion
Common Stock
2015-07-28+20,833→ 177,932 total - Conversion
Series B Preferred Stock
2015-07-28−50,000→ 0 total→ Common Stock (20,833 underlying) - Conversion
Series C Preferred Stock
2015-07-28−220,700→ 0 total→ Common Stock (91,956 underlying) - Exercise/Conversion
Common Stock
2015-07-27$2.31/sh+28,897$66,752→ 155,456 total - Conversion
Common Stock
2015-07-28+91,956→ 369,888 total - Exercise of In-Money
Common Stock Warrant (Right to Buy)
2015-07-27−16,408→ 0 totalExercise: $0.02Exp: 2016-10-19→ Common Stock (16,408 underlying)
Footnotes (3)
- [F1]Each share of the Issuer's Series B preferred stock, Series B-1 preferred stock and Series C preferred stock was automatically converted on a 2.4-for-1 basis into common stock immediately prior to the closing of the Issuer's initial public offering. The shares of Series B preferred stock, Series B-1 preferred stock and Series C preferred stock had no expiration date.
- [F2]The warrant was exercisable at any time at the holder's election.
- [F3]This stock option was fully vested and exercisable.